Corza Medical Archives - Medical Design Sourcing

Corza Medical expands leadership team with three new executives

Corza Medical today announced it appointed three new executives to its leadership team.

Westwood, Massachusetts-based Corza Medical appointed Thierry Leclercq as senior VP of biosurgery, James Getty as VP of technology and Jack Simmons as senior VP of ophthalmology.

“Corza Medical is intensely focused on making every customer interaction remarkable, earning client’s trust through our high-quality technologies, and delivering outstanding value. With the foundation of Corza Medical now established, we are excited to announce the next level of leadership reporting to chief executive officer, Tom Testa,” Gregory Lucier, chair of Corza Medical, said in a news release.

Leclercq has more than 30 years of experience at GE Healthcare where he was president and CEO of GE LifeCare Solutions. He was also previously CEO of Dutch Ophthalmic Research Center, NL, which is an ophthalmic vitreoretinal surgical device leader. Leclercq will be based in Eur…

Corza Medical acquires Katena Products

Private equity firm GTCR announced today that Corza Medical acquired Katena Products and its ophthalmic surgery offerings.

Katena develops ophthalmic products used across cataract, glaucoma and corneal surgeries, including precision surgical instruments, single-use devices and specialty biologics, according to a news release. The company, which has more than 200 employees across North America and Europe, has sold products in more than 110 countries to more than 5,000 customers.

Corza said in the release that the acquisition expands its surgical product portfolio while adding significant scale, product breadth and infrastructure to its ophthalmic surgery segment. It’s the first add-on acquisition for Corza since its formation in January 2021, with the company aiming to take on the “almost monopolistic” leaders in medtech. Corza was formed through the merger of Surgical Specialties and TachoSil, a carve-out from Takeda.

R…

DTW Podcast: Zimmer Biomet slims, Corza Medical grows in pursuit of grabbing market share

In this week’s DeviceTalks Weekly Podcast, Rich Newitter, managing director at SVB Leerink, says Zimmer Biomet’s decision to spin out its spinal and dental business will accelerate its already impressive market share grab in its core orthopedics industry.

Dewitter says CEO Bryan Hanson brings a tried-and-true diversification model used by companies like his former employer, Covidien. The spinout of the spinal and dental businesses into a NewCo will allows the company to focus more resources on selling knee and hip implants as well as building out an impressive robotics franchise and a potentially sector-leading line of digital tools and sensors.

“Zimmer has effectively gone from a share loser for almost a decade leading up to when Bryan Hanson took over to a share-taking position,” he said in an interview with Chris Newmarker, executive editor of life sciences. “This most recent quarter, their share gains have widened quite dramatically.”

In …

DTW Podcast: Zimmer Biomet slims, Corza Medical grows in pursuit of grabbing market share

In this week’s DeviceTalks Weekly Podcast, Rich Newitter, managing director at SVB Leerink, says Zimmer Biomet’s decision to spin out its spinal and dental business will accelerate its already impressive market share grab in its core orthopedics industry.

Dewitter says CEO Bryan Hanson brings a tried-and-true diversification model used by companies like his former employer, Covidien. The spinout of the spinal and dental businesses into a NewCo will allows the company to focus more resources on selling knee and hip implants as well as building out an impressive robotics franchise and a potentially sector-leading line of digital tools and sensors.

“Zimmer has effectively gone from a share loser for almost a decade leading up to when Bryan Hanson took over to a share-taking position,” he said in an interview with Chris Newmarker, executive editor of life sciences. “This most recent quarter, their share gains have widened quite dramatically.”

In …

Corza Medical set to take on “almost monopolistic” surgical giants

Corza Medical, a new venture backed by the financial firepower of private equity giant GTCR, is looking to build a surgical tool supplier that its executive chairman Greg Lucier says can compete with “almost monopolistic” leaders in the space.

To mount the challenge, Corza acquired Surgical Specialties Corp., a supplier of surgical sutures and ophthalmic knives. Corza will use this beachhead in Westwood, Mass., to build a pipeline of acquired assets including TachoSil, a surgical patch product line Corza acquired from Takeda Pharmaceuticals last year.

In an interview with the DeviceTalks Weekly podcast, Lucier, the former CEO of spinal company NuVasive (NSDQ:NUVA) and diagnostic company Life Technologies, said management believes “there is an opening for a pretty good-sized surgical tools and technologies company to compete against the Ethicons and the Medtronics of the world.”

Lucier said the two Goliaths have reached a size that makes them “almost mono…

Corza Medical set to take on “almost monopolistic” surgical giants

Corza Medical, a new venture backed by the financial firepower of private equity giant GTCR, is looking to build a surgical tools supplier that its Executive Chairman Greg Lucier says can compete with “almost monopolistic” leaders in the space.

To mount the challenge, Corza acquired Surgical Specialties Corp., a supplier of surgical sutures and ophthalmic knives. Corza will use this beachhead in Westwood, Mass. to build a pipeline of acquired assets including TachoSil, a surgical patch product line Corza had acquired from Takeda Pharmaceuticals last year.

In an interview with the DeviceTalks Weekly podcast, Lucier, the former CEO of spinal company Nuvasive and diagnostic leader Life Technologies, says management believes “there is an opening for a pretty good-sized surgical tools and technologies company to compete against the Ethicons and the Medtronics of the world.”

Lucier said the two Goliaths have reached a size that makes them “almost monopolistic …